We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Events

09 Apr 2024 - 12 Apr 2024
15 Apr 2024 - 17 Apr 2024
23 Apr 2024 - 26 Apr 2024

Certification Enables Development of New Technology in Next-Gen Immunodiagnostics

By LabMedica International staff writers
Posted on 06 Sep 2016
Print article
Image: The Sgx Clarity System, being developed for highly sensitive next-generation immunodiagnostic detection, provides simple and intuitive operation (Photo courtesy of Singulex).
Image: The Sgx Clarity System, being developed for highly sensitive next-generation immunodiagnostic detection, provides simple and intuitive operation (Photo courtesy of Singulex).
ISO (International Organization for Standardization) 13485:2012 Certification has been granted by NSAI to help ensure high standard development of a proprietary Single Molecule Counting (SMC) technology for clinical use as a next-generation immunodiagnostic platform.

Singulex, Inc. (Alameda, CA, USA) is developing its SMC technology for clinical immunodiagnostics and scientific discovery, to enable physicians and researchers to detect disease biomarkers that were previously undetectable. Singulex Clinical Lab Testing Services currently provide a comprehensive menu of advanced cardiovascular disease testing utilizing SMC technology.

"Receiving ISO 13485 certification validates the quality processes we have put in place to build Singulex into the Next Generation Immunodiagnostics Company, and are very pleased that NSAI recognizes Singulex as meeting the highest quality of standards," said Guido Baechler, Singulex president and CEO.

The certification from this independent organization ensures quality, safety, and efficiency, and prepares Singulex for market entry of its Sgx Clarity System, an automated in vitro diagnostics platform currently under development for hospital and reference labs worldwide. The system is currently undergoing evaluation in Europe and may achieve the CE-Mark by the end of Q1 2017. Singulex is planning to submit the Sgx Clarity System to the FDA in early 2017.

"Achieving ISO certification ensures that laboratorians, physicians, and patients will receive the highest quality diagnostic information as we commercialize the Sgx Clarity System, the most sensitive fully-automated immunoassay analyzer," said Baechler.

Singulex's SMC technology, which will power next-generation immunodiagnostics delivered through the Sgx Clarity System, provides immunodiagnostic assays that are 100 times more sensitive than those on other testing platforms, enabling unprecedented security to medical decisions. The sensitivity of SMC technology allows physicians to measure what they could not see before, allowing to better understand all stages of disease and help determine a patient's health status, including disease risk. SMC technology has been scientifically established through clinical studies involving greater than 100,000 patients, resulting in greater than 110 peer reviewed publications.

Related Links:
Singulex


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Specimen Collection & Transport
Complement 3 (C3) Test
GPP-100 C3 Kit
New
Gold Member
Magnetic Bead Separation Modules
MAG and HEATMAG

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: MOF materials efficiently enrich cfDNA and cfRNA in blood through simple operational process (Photo courtesy of Science China Press)

Blood Circulating Nucleic Acid Enrichment Technique Enables Non-Invasive Liver Cancer Diagnosis

The ability to diagnose diseases early can significantly enhance the effectiveness of clinical treatments and improve survival rates. One promising approach for non-invasive early diagnosis is the use... Read more

Hematology

view channel
Image: The low-cost portable device rapidly identifies chemotherapy patients at risk of sepsis (Photo courtesy of 52North Health)

POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy

Neutropenia, a decrease in neutrophils (a type of white blood cell crucial for fighting infections), is a frequent side effect of certain cancer treatments. This condition elevates the risk of infections,... Read more

Pathology

view channel
Image: The OvaCis Rapid Test discriminates benign from malignant epithelial ovarian cysts (Photo courtesy of INEX)

Intra-Operative POC Device Distinguishes Between Benign and Malignant Ovarian Cysts within 15 Minutes

Ovarian cysts represent a significant health issue for women globally, with up to 10% experiencing this condition at some point in their lives. These cysts form when fluid collects within a thin membrane... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.